Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma plc (~292)

  Print      Mail a friend       Annual reports

Monday 04 June, 2007

Antisoma plc

Positive data from ASA404 prostate cancer trial...

London, UK & Chicago, IL: 3 June 2007 - Antisoma plc (LSE: ASM, US
OTC: ATSMY) announces the presentation today at ASCO of new, positive
data from its randomised phase II trial testing the addition of
ASA404 (formerly AS1404) to first-line docetaxel chemotherapy in
hormone-refractory prostate cancer.

Final PSA data show that ASA404 greatly increased PSA response rate -
the proportion of patients showing a sustained 50% reduction in blood
levels of the prostate cancer biomarker PSA. Seventy patients were
evaluable for PSA response. The response rate was 59% in men treated
with ASA404 plus docetaxel versus 37% in the control group, who
received docetaxel alone. The proportion of patients showing
progression by PSA was 16% in the ASA404 group and 37% in the control
group, a more marked difference than that seen in preliminary
findings from the trial.

PSA reductions were more profound and of more rapid onset in patients
who received ASA404. PSA fell by a median of 79% in the ASA404 group
and 36% in the control group. Among patients whose PSA fell, maximum
reduction was achieved in a median of 96 days in the ASA404 group and
120 days in the control group.

Today's presentation also includes safety findings from the trial.
These remain consistent with earlier reports in showing that addition
of ASA404 to chemotherapy was generally well tolerated.

Data are presented by Dr Roberto Pili of Johns Hopkins University and
Professor Mark Rosenthal of the Royal Melbourne Hospital, Victoria,
Australia. Professor Rosenthal said: "These PSA data clearly suggest
that activity is improved when ASA404 is added to first-line
docetaxel therapy in patients with hormone-refractory prostate
cancer. We will very soon see whether the PSA effect translates into
progression and survival benefits."

Further data from the prostate cancer trial, including 1-year
survival findings, will be available before the end of October, as
will further data from two other studies in ovarian and lung cancers.
Final data from a randomised study in lung cancer were reported in
2006. These showed a 5.2-month extension in median survival when
ASA404 was added to carboplatin and paclitaxel.

ASA404 was recently licensed to Novartis AG, who will be conducting
all further development including a phase III trial in lung cancer
scheduled to start patient recruitment early in 2008.

Glyn Edwards, CEO of Antisoma, said: "This is a really exciting time
with ASA404. We have already seen impressive survival data in lung
cancer and have forged a strong partnership with Novartis to take the
drug forward. The latest data from the prostate cancer trial are very
encouraging as we look forward to seeing survival data from this and
other studies over the next few months."

Prostate cancer is among the most prevalent cancers in the developed
world. It often responds initially to hormonal therapies, but each
year some 200,000 men across the US, Europe and Japan develop
'hormone-refractory' disease.  The taxane drug docetaxel has become
an important treatment for such hormone-refractory prostate cancer.
ASA404 has shown synergistic anti-cancer effects in combination with
docetaxel and other taxanes in preclinical tests.

A copy of the poster presented at ASCO is available at


Glyn Edwards, Chief Executive Officer
Daniel Elger, Director of Communications          +44 7909 915 068
Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye
Dietrich                                          +44 (0)20 7466 5000
Buchanan Communications

Brian Korb                                        +1  212 477 9007
The Trout Group

Antisoma disclaimer
Certain matters discussed in this statement are forward looking
statements that are subject to a number of risks and uncertainties
that could cause actual results to differ materially from results,
performance or achievements expressed or implied by such statements.
These risks and uncertainties may be associated with product
discovery and development, including statements regarding the
company's clinical development programmes, the expected timing of
clinical trials and regulatory filings. Such statements are based on
management's current expectations, but actual results may differ

PSA and PSA responses
PSA is a protein, prostate-specific antigen. Levels of PSA in the
blood are used in the diagnosis of prostate cancer and the tracking
of responses to its treatment. PSA is one of the most widely
recognised disease markers in oncology, and PSA responses have been
related to clinical outcomes in numerous studies.

PSA response is defined as a 50% or greater reduction in PSA level
from baseline and progression by PSA is defined as a 25% or greater
increase from the lower of baseline or PSA nadir. This is in
accordance with the Bubley criteria (Eligibility and response
guidelines for phase II clinical trials in androgen-independent
prostate cancer: recommendations from the Prostate-Specific Antigen
Working Group. Journal of Clinical Oncology 1999, Volume 17, pp

Background on ASA404
ASA404 (DMXAA) is a small-molecule vascular disrupting agent which
targets the blood vessels that nourish tumours. The drug was
discovered by Professors Bruce Baguley and William Denny and their
teams at the Auckland Cancer Society Research Centre, University of
Auckland, New Zealand. It was in-licensed by Antisoma from Cancer
Research Ventures Limited (now Cancer Research Technology), the
development and commercialisation company of the Cancer Research
Campaign (now Cancer Research UK), in August 2001. CRUK had supported
two phase I studies in the UK and New Zealand. ASA404 has shown a
substantial survival benefit in patients with non-small cell lung
cancer when added to paclitaxel-based chemotherapy in a randomised
phase II study. Worldwide rights to the drug were licensed to
Novartis AG in April 2007.

Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. Please visit for further information.




a d v e r t i s e m e n t